These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 1627763)

  • 1. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.
    Besarab A; Flaharty KK; Erslev AJ; McCrea JB; Vlasses PH; Medina F; Caro J; Morris E
    J Am Soc Nephrol; 1992 Mar; 2(9):1405-16. PubMed ID: 1627763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin requirements predict mortality in hemodialysis patients.
    Zhang Y; Thamer M; Stefanik K; Kaufman J; Cotter DJ
    Am J Kidney Dis; 2004 Nov; 44(5):866-76. PubMed ID: 15492953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, masked study of weekly erythropoietin dosing in preterm infants.
    Ohls RK; Roohi M; Peceny HM; Schrader R; Bierer R
    J Pediatr; 2012 May; 160(5):790-5.e1. PubMed ID: 22137666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer.
    Tsukuda M; Mochimatsu I; Nagahara T; Kokatsu T; Sawaki S; Kubota A; Furkawa M; Arai Y
    Cancer Immunol Immunother; 1993; 36(1):52-6. PubMed ID: 8422668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the effects of intravenous and subcutaneous Erythropoietin on blood indices in hemodialysis patients.
    Ghasemi F; Abdi A; Salari N; Tohidi MR; Faraji A
    Sci Rep; 2019 Feb; 9(1):2284. PubMed ID: 30783118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
    Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
    Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets.
    Fishbane S; Besarab A
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1274-82. PubMed ID: 17942772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Chung EY; Palmer SC; Saglimbene VM; Craig JC; Tonelli M; Strippoli GF
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD010590. PubMed ID: 36791280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proof-of-concept study on improved efficacy of rHuEPO administered as a long-term infusion in rats.
    Szczesny D; Mołoniewicz K; Markuszewski MJ; Wiczling P
    Pharmacol Rep; 2020 Oct; 72(5):1264-1270. PubMed ID: 32748255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study.
    Garimella PS; Katz R; Patel KV; Kritchevsky SB; Parikh CR; Ix JH; Fried LF; Newman AB; Shlipak MG; Harris TB; Sarnak MJ;
    Circ Heart Fail; 2016 Jan; 9(1):e002124. PubMed ID: 26721912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
    Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
    BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Peginesatide Injection on QTc Interval in Healthy Adults.
    Czerniak R; Kukulka M; Wu JT; Qiu P
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):449-455. PubMed ID: 26161294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents.
    Yan X; Krzyzanski W
    CPT Pharmacometrics Syst Pharmacol; 2013 Aug; 2(8):e62. PubMed ID: 23924820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.
    Doshi S; Krzyzanski W; Yue S; Elliott S; Chow A; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2013 Dec; 52(12):1063-83. PubMed ID: 23912564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.
    Yan X; Lowe PJ; Fink M; Berghout A; Balser S; Krzyzanski W
    J Clin Pharmacol; 2012 Nov; 52(11):1624-44. PubMed ID: 22162538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human epoetin beta in the treatment of renal anemia.
    Locatelli F; Pozzoni P; Vecchio LD
    Ther Clin Risk Manag; 2007 Jun; 3(3):433-9. PubMed ID: 18488073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.
    Deicher R; Hörl WH
    Drugs; 2004; 64(5):499-509. PubMed ID: 14977387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.
    Harris DC
    Pharmacoeconomics; 1994 Jan; 5(1):18-28. PubMed ID: 10146863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?
    Peys F
    Pharm World Sci; 1997 Apr; 19(2):73-81. PubMed ID: 9151345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?
    Peys F
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):189-200. PubMed ID: 8839694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.